Cancer cells undergo accelerated evolutionary changes; thus, under the pressure of novel generations of EGFR TKIs, we should expect to see new mechanisms of resistance.
Arkadiusz Z. Dudek, MD, PhD
Advertisement
Articles by Arkadiusz Z. Dudek, MD, PhD
Advertisement
Latest Updated Articles
- Management of Resistance to EGFR TKI–Targeted Therapy of Lung Cancer: Lessons in Monitoring Cancer Evolution
Published: July 16th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
3
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
